BioSpace News Archive

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.

This financing provides substantial incremental capital to fund AEGEA’s operations while it prepares to launch commercially in the US.

SI-BONE announced that BCBSA, after an extensive review of all existing peer-reviewed published clinical safety and effectiveness data, has assigned triangular implants for SI joint fusion a “Moderate” quality evidence recommendation.

The cash will support expansion in translational informatics, clinical trials, and broadened use of biomedical data.

AgeX today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging.

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon sent the following annual letter to his colleagues at Intrexon.

Cue Biopharma today announced the closing of its initial public offering of 8,820,710 shares of its common stock at a public offering price of $7.50 per share on December 27, 2017.

Under the agreement, Janssen will supply daratumumab for a recently added combination dosing cohort in Syros’ ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

RenalGuard Solutions today reported positive results from a first-in-man feasibility study focusing on a novel use of the RenalGuard System to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload.